Risk of Neuromyelitis Optica in Patients with Other Autoimmune Diseases
Patients with other autoimmune diseases have a significantly elevated risk of developing neuromyelitis optica spectrum disorder (NMOSD), with approximately 24-37% of NMOSD patients having coexisting autoimmune conditions, compared to only 5-8% in other neuroinflammatory diseases. 1, 2
Most Commonly Associated Autoimmune Diseases
The autoimmune conditions most frequently coexisting with NMOSD include:
Systemic Autoimmune Diseases
- Sjögren's Syndrome (SS) - Most frequently reported systemic autoimmune disease associated with NMOSD 3
- Systemic Lupus Erythematosus (SLE) - Second most common systemic association, with optic neuritis being the most common neurological manifestation (21-48% of SLE myelopathy cases) 4, 3
Organ-Specific Autoimmune Diseases
- Autoimmune thyroid diseases - Most common non-neurological organ-specific association 3
- Myasthenia gravis - Most frequently reported neurological organ-specific autoimmune disease 3
Additional Associations
- Antiphospholipid syndrome
- Autoimmune hepatitis
- Primary adrenal insufficiency (Addison disease)
- Celiac disease 5, 6
Causal Relationships and Risk Factors
Importantly, Mendelian randomization analysis demonstrates that autoimmune thyroid disease, SLE, and Sjögren's syndrome are causally associated with NMOSD susceptibility, but NMOSD does not cause these autoimmune diseases - meaning the autoimmune disease comes first and increases NMOSD risk. 7
Specific Risk Factors for Relapse in Autoimmune-Associated NMOSD:
- Age under 50 years at onset
- Concurrent SLE diagnosis
- Longer duration of SLE before NMOSD presentation 2
Clinical Characteristics of Autoimmune-Associated NMOSD
Patients with autoimmune disease-associated NMOSD (AD-NMOSD) show distinct features 2, 8:
Laboratory differences:
- Lower white blood cell counts
- Lower hemoglobin levels
- Lower platelet counts
- Lower immunoglobulin G levels
- Lower C-reactive protein levels
- Lower serum albumin
Clinical features:
- Higher frequency of grouped comorbidities
- More sensory symptoms
- Higher prevalence of antinuclear antibodies, anti-dsDNA, anti-RNP, and antiphospholipid antibodies
- More spinal cord edema on imaging
- More white matter occipital lesions
Relapse patterns:
- Female patients with coexisting autoimmune disease have higher relapse rates within the first year 1
- Patients with autoimmune disease diagnosed before NMOSD onset have 1.5x higher risk of relapse in the first year and first 2 years 1
- AQP4-antibody positive patients have shorter time to first relapse (HR = 2.4) 1
Important Clinical Pitfalls
A critical caveat: Despite the strong association with many autoimmune diseases, inflammatory bowel disease (IBD) appears to be significantly underrepresented in NMOSD patients (0.3% in seropositive NMOSD vs 1.5% in MS patients), suggesting possible protective mechanisms or distinct immunopathology 9. This is particularly notable given that IBD shares similar B-cell mediated pathophysiology.
Screening Recommendations
For patients with established autoimmune diseases (particularly SLE, Sjögren's syndrome, or autoimmune thyroid disease):
- Maintain high clinical suspicion for NMOSD when neurological symptoms develop
- Test for AQP4-IgG antibodies using cell-based assays when optic neuritis, myelitis, or area postrema syndrome occurs 10, 11, 12
- Perform contrast-enhanced MRI of brain and spine when CNS symptoms emerge
- Consider testing even with atypical presentations, as coexisting autoimmune disease may modify clinical phenotype
For patients with newly diagnosed NMOSD:
- Screen for thyroid dysfunction (TSH, thyroid antibodies)
- Evaluate for SLE (ANA, anti-dsDNA, complement levels)
- Assess for Sjögren's syndrome (anti-SSA/SSB antibodies, Schirmer test)
- Check for antiphospholipid antibodies
- Consider myasthenia gravis screening if bulbar or respiratory symptoms present 5, 6
Management Implications
The presence of coexisting autoimmune disease affects treatment strategy 2, 8:
- Similar response to acute treatment (IV methylprednisolone, plasma exchange)
- May require more aggressive maintenance immunosuppression due to higher early relapse risk
- Treatment must address both NMOSD and the coexisting autoimmune condition
- Closer monitoring needed in first 2 years after NMOSD onset
- Despite various treatments, no significant differences in long-term relapse rates between AD-NMOSD and primary NMOSD, emphasizing need for individualized approaches
The MHC class I-related biological processes and interferon-gamma-mediated signaling pathways appear central to the pathogenesis of NMOSD coexisting with these autoimmune diseases 7.